{"id":9735,"date":"2026-10-29T17:01:17","date_gmt":"2026-10-29T11:31:17","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/caplipoint-share-price-today-2026-10-29\/"},"modified":"2026-10-29T17:01:19","modified_gmt":"2026-10-29T11:31:19","slug":"caplipoint-share-price-today-2026-10-29","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/caplipoint-share-price-today-2026-10-29\/","title":{"rendered":"Caplin Point Laboratories Share Price Today: Why CAPLIPOINT Is Rising 0.56% | 29 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: CAPLIPOINT<\/strong> \u00b7 29 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,376.10<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+0.56%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,409.80 \/ \u20b92,344.10<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,362.80<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>85,348<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>29 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Caplin Point Laboratories Ltd. (CAPLIPOINT) inched higher today, gaining 0.56% to settle at \u20b92,376.10 compared to its previous close of \u20b92,362.80. The stock oscillated within a day&#x27;s range of \u20b92,344.10 and \u20b92,409.80, opening slightly lower at \u20b92,358.40.<\/li>\n<li>Caplin Point Laboratories submitted the scrutinizer report and voting results for its 35th Annual General Meeting held on 25 September 2026. Shareholders successfully approved the adoption of standalone and consolidated financial statements, final dividend of \u20b94 per equity share, and various managerial appointments including Dr. Sridhar Ganesan as Managing Director.<\/li>\n<li>Trading volume was 0.77 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Caplin Point Laboratories share price rising on 29 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Caplin Point Laboratories Ltd. (CAPLIPOINT) inched higher today, gaining 0.56% to settle at \u20b92,376.10 compared to its previous close of \u20b92,362.80. The stock oscillated within a day&#x27;s range of \u20b92,344.10 and \u20b92,409.80, opening slightly lower at \u20b92,358.40.<\/p>\n<p class=\"wt-copy\">The broader market and sector benchmarks displayed positive momentum during the session, with the Nifty advancing 1.05% and the Nifty Pharma sector index gaining 0.64%. Caplin Point&#x27;s modest 0.56% gain kept pace with the broader pharmaceutical sector&#x27;s performance, though it trailed the broader Nifty benchmark. Over a 5-day trading window, the stock has risen 5.65%, while maintaining a 20-day return profile of -13.41%.<\/p>\n<p class=\"wt-copy\">On the corporate front, while no single new price-sensitive announcement was released today to directly explain the price action, recent company filings show operational progress, including the voting results of its 35th Annual General Meeting held on 25 September 2026 where shareholders approved a final dividend of \u20b94 per equity share alongside key managerial re-appointments. Additionally, earlier in September, subsidiary Caplin One Labs received GMP compliance certification from INVIMA, providing broader context to the company&#x27;s export and regulatory footprint.<\/p>\n<p class=\"wt-copy\">85,348 shares traded by 29 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 1.11 lakh shares (0.77 times). The five-day average daily volume was 68,944 shares. Separately, the NSE report for 28 October 2026 showed 19,869 shares delivered, representing 50.32% of that day\u2019s traded volume. The same report recorded 7,977 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Stock-specific stabilization and sector alignment<\/strong><\/p>\n<p class=\"wt-copy\">With no direct catalyst published today, the 0.56% gain aligns with steady participation in line with the Nifty Pharma sector advance of 0.64%, alongside a moderate rebound following recent 20-day weakness.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">AGM Voting Results and Final Dividend Approval<\/div>\n<div class=\"wt-card-date\">26 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Caplin Point Laboratories submitted the scrutinizer report and voting results for its 35th Annual General Meeting held on 25 September 2026. Shareholders successfully approved the adoption of standalone and consolidated financial statements, final dividend of \u20b94 per equity share, and various managerial appointments including Dr. Sridhar Ganesan as Managing Director.<\/p>\n<p class=\"wt-copy\">Confirms formal shareholder approval for capital returns and leadership continuity for the pharmaceutical exporter.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/CAPLINPOINT_25092026191305_Scrutinizer_Report_signed_final.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Subsidiary Receives INVIMA GMP Certification<\/div>\n<div class=\"wt-card-date\">1 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Caplin One Labs Limited, a subsidiary company, received Good Manufacturing Practices compliance certification from INVIMA. This regulatory clearance strengthens the company&#x27;s standing and export capabilities in regulated international markets.<\/p>\n<p class=\"wt-copy\">Expands compliance credentials for manufacturing facilities supporting international market expansion.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Order \/ business win<\/div>\n<div class=\"wt-card-date\">25 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/CAPLINPOINT_24092026183956_Spult_in_volume_sd.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Management \/ board update<\/div>\n<div class=\"wt-card-date\">12 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on August 12, 2026, recommended Final Dividend of Rs. 4 per equity share.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/CAPLINPOINT_12082026134040_Outcome.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">70.57%<\/div>\n<div class=\"wt-note\">70.57% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">5.73%<\/div>\n<div class=\"wt-note\">5.75% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">7.93%<\/div>\n<div class=\"wt-note\">8.24% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742873_21102026033543_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 1.64% on 30 September 2026. This compares with 2.03% on 30 June 2026, a change of -0.39 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 20 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">UTI NIFTY 500 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">10.46 lakh shares \u00b7 1.38%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742873_21102026033543_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of international regulatory approvals and subsequent export dispatch data from subsidiaries like Caplin One Labs and Caplin Steriles.<\/li>\n<li>Delivery volume trends and cash participation relative to the 20-day average volume.<\/li>\n<li>Upcoming financial results and commentary on margin performance across Latin American and emerging markets.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/caplipoint\/\">More Caplin Point Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Caplin Point Laboratories company news?<\/h3>\n<p class=\"wt-copy\">Caplin Point Laboratories submitted the scrutinizer report and voting results for its 35th Annual General Meeting held on 25 September 2026. Shareholders successfully approved the adoption of standalone and consolidated financial statements, final dividend of \u20b94 per equity share, and various managerial appointments including Dr. Sridhar Ganesan as Managing Director.<\/p>\n<h3>How strong was Caplin Point Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">85,348 shares traded, 0.77 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/caplipoint-share-price-today-2026-10-29\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/caplipoint-share-price-today-2026-10-29\/\"}, \"headline\": \"Caplin Point Laboratories Share Price Today: Why CAPLIPOINT Is Rising 0.56% | 29 October 2026\", \"description\": \"Caplin Point Laboratories share price rose 0.56% to \u20b92,376.10 today. See why CAPLIPOINT is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-29T17:01:04.511083+05:30\", \"dateModified\": \"2026-10-29T17:01:04.511083+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Caplin Point Laboratories\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"CAPLIPOINT\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/caplipoint-company-news-2026-10-29.jpg\"]}]}<\/script><!-- wt-article-record:{\"recent_news\":[{\"summary\":\"Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.\",\"category\":\"Spurt in Volume\",\"date\":\"24-Sep-2026 18:45:06\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CAPLINPOINT_24092026183956_Spult_in_volume_sd.pdf\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.\",\"category\":\"Spurt in Volume\",\"date\":\"24-Sep-2026 17:41:37\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"-\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"Change in Director(s) of the company.\",\"category\":\"Change in Director(s)\",\"date\":\"12-Aug-2026 14:58:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CAPLINPOINT_12082026145814_Change_in_Director.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":3},{\"summary\":\"Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on August 12, 2026, recommended Final Dividend of Rs. 4 per equity share.\",\"category\":\"Dividend\",\"date\":\"12-Aug-2026 13:41:16\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CAPLINPOINT_12082026134040_Outcome.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"promoter_pledge\":{\"summary\":\"The promoter\/promoter-group disclosure states that the shares covered by the filing were free from encumbrance.\",\"events\":[{\"summary\":\"Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, 5 th Floor, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400051 Scrip Code: CAPLIPOINT Dear Sir\/Madam, Sub: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, a declaration is hereby made that no encumbrance on shares of Caplin Point Laboratories Limited has been created, directly or indirectly, during the financial year ended March 31, 2026. Details of Entity\/Person on whose behalf the declaration is being submitted Name of Entity\/Person Category Mr. C C Paarthipan Promoter Ms. P Vijayalakshmi Promoter Group Mr. Ashok Gorkey Partheeban Promoter Group Mr. Partheeban Vivek Siddarth Promoter Group May India Property Private Limited Promoter Group Kiraviz Properties & Consultancy LLP Promoter Group First Dimension Holdings Private Limited Promoter Group For and on behalf of Promoter and Promoter Group Partheeban Vivek Siddarth Vice Chairman and Director CC, The Audit Committee, Caplin Point Laboratories Limited, No.3, Ashvich Tow\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"16-Jun-2026 18:25:30\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_bbodade_06052026162232_CAPLIPOINT.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":70.57,\"public_pct\":29.43,\"fii_pct\":5.73,\"dii_pct\":2.2,\"mf_pct\":1.64,\"institutional_pct\":7.93,\"noninst_pct\":21.5,\"mf_scheme_count\":20,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"UTI NIFTY 500 INDEX FUND\",\"shares\":1046374,\"pct\":1.38}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742873_21102026033543_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":70.57,\"previous_fii_pct\":5.75,\"previous_dii_pct\":2.49,\"previous_mf_pct\":2.03,\"previous_institutional_pct\":8.24,\"previous_mf_scheme_count\":19,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Caplin Point Laboratories share price rose 0.56% to \u20b92,376.10 today. See why CAPLIPOINT is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":9734,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Caplin Point Laboratories Share Price Today: Why CAPLIPOINT Is Rising 0.56% | 29 October 2026","_witty_meta_description":"Caplin Point Laboratories share price rose 0.56% to \u20b92,376.10 today. See why CAPLIPOINT is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Caplin Point Laboratories share price today","_witty_reason_label":"Stock-specific stabilization and sector alignment","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[366],"class_list":["post-9735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-caplipoint"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=9735"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9735\/revisions"}],"predecessor-version":[{"id":9736,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9735\/revisions\/9736"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/9734"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=9735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=9735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=9735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}